Department of Regenerative Cardiology, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
Cell Death Differ. 2012 May;19(5):743-55. doi: 10.1038/cdd.2011.172. Epub 2011 Dec 2.
Expansion of human stem cells before cell therapy is typically performed at 20% O(2). Growth in these pro-oxidative conditions can lead to oxidative stress and genetic instability. Here, we demonstrate that culture of human mesenchymal stem cells at lower, physiological O(2) concentrations significantly increases lifespan, limiting oxidative stress, DNA damage, telomere shortening and chromosomal aberrations. Our gene expression and bioenergetic data strongly suggest that growth at reduced oxygen tensions favors a natural metabolic state of increased glycolysis and reduced oxidative phosphorylation. We propose that this balance is disturbed at 20% O(2), resulting in abnormally increased levels of oxidative stress. These observations indicate that bioenergetic pathways are intertwined with the control of lifespan and decisively influence the genetic stability of human primary stem cells. We conclude that stem cells for human therapy should be grown under low oxygen conditions to increase biosafety.
细胞治疗前通常将人类干细胞在 20%氧气浓度下进行扩增。在这些促氧化条件下的生长会导致氧化应激和遗传不稳定性。在这里,我们证明在较低的生理氧气浓度下培养人类间充质干细胞可以显著延长寿命,限制氧化应激、DNA 损伤、端粒缩短和染色体异常。我们的基因表达和生物能量数据强烈表明,在较低氧张力下的生长有利于增加糖酵解和减少氧化磷酸化的自然代谢状态。我们提出,在 20%氧气浓度下,这种平衡被打破,导致氧化应激水平异常升高。这些观察结果表明,生物能量途径与寿命控制交织在一起,并对人类原代干细胞的遗传稳定性产生决定性影响。我们得出结论,用于人类治疗的干细胞应在低氧条件下生长,以提高生物安全性。